Peripartum cardiomyopathy--a new treatment option by inhibition of prolactin secretion.
Author(s): Jahns BG, Stein W, Hilfiker-Kleiner D, Pieske B, Emons G
Affiliation(s): Department of Gynecology and Obstetrics, Georg-August-University, Gottingen, Germany. boriana_jahns@yahoo.com
Publication date & source: 2008-10, Am J Obstet Gynecol., 199(4):e5-6.
Publication type: Case Reports
Peripartum cardiomyopathy (PPCM) is a rare disease of unclear etiology with a frequent poor outcome, despite optimal medical therapy. Recent experimental data implicate a causal role of prolactin. We report a patient with PPCM who responded well to treatment with Bromocriptine in addition to standard therapy of heart failure.
|